Global Hereditary Angioedema Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hereditary Angioedema Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Hereditary angioedema is a rare disease and is mostly mistaken for common allergic reactions and abdominal pain. This mainly on account of the lack of knowledge among both physicians and patients about the condition. About 40% of the affected patients are diagnosed correctly with hereditary angioedema in the US and Europe. With progress in diagnostic field and different initiatives undertaken by patient bodies and industry players to spread awareness, the market for hereditary angioedema is projected to grow.
Hereditary Angioedema report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Hereditary Angioedema market is projected to reach US$ 2724.1 million in 2034, increasing from US$ 1656.7 million in 2022, with the CAGR of 7.3% during the period of 2024 to 2034. Demand from Retail Pharmacies and Hospital Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Hereditary Angioedema industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Hereditary Angioedema key manufacturers include Pharming Group NV, Takeda, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc., etc. Pharming Group NV, Takeda, CSL Limited are top 3 players and held % sales share in total in 2022.
Hereditary Angioedema can be divided into C1 Esterase Inhibitor, Kallikrein Inhibitor and Selective Bradykinin B2 Receptor Antagonist,, etc. C1 Esterase Inhibitor is the mainstream product in the market, accounting for % sales share globally in 2022.
Hereditary Angioedema is widely used in various fields, such as Retail Pharmacies, Hospital Pharmacies and Online Pharmacies,, etc. Retail Pharmacies provides greatest supports to the Hereditary Angioedema industry development. In 2022, global % sales of Hereditary Angioedema went into Retail Pharmacies filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hereditary Angioedema market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Distribution Channel and Regions Listed in the Report
Pharming Group NV
Takeda
CSL Limited
iBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Segment by Type
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Segment by Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Hereditary Angioedema market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Hereditary Angioedema, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Hereditary Angioedema industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Hereditary Angioedema in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Distribution Channel, Volume and Revenue analysis of Each Distribution Channel in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Hereditary Angioedema introduction, etc. Hereditary Angioedema Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Hereditary Angioedema market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Hereditary Angioedema report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Hereditary Angioedema market is projected to reach US$ 2724.1 million in 2034, increasing from US$ 1656.7 million in 2022, with the CAGR of 7.3% during the period of 2024 to 2034. Demand from Retail Pharmacies and Hospital Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Hereditary Angioedema industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Hereditary Angioedema key manufacturers include Pharming Group NV, Takeda, CSL Limited, iBio Inc., BioCryst Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc., etc. Pharming Group NV, Takeda, CSL Limited are top 3 players and held % sales share in total in 2022.
Hereditary Angioedema can be divided into C1 Esterase Inhibitor, Kallikrein Inhibitor and Selective Bradykinin B2 Receptor Antagonist,, etc. C1 Esterase Inhibitor is the mainstream product in the market, accounting for % sales share globally in 2022.
Hereditary Angioedema is widely used in various fields, such as Retail Pharmacies, Hospital Pharmacies and Online Pharmacies,, etc. Retail Pharmacies provides greatest supports to the Hereditary Angioedema industry development. In 2022, global % sales of Hereditary Angioedema went into Retail Pharmacies filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hereditary Angioedema market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Distribution Channel and Regions Listed in the Report
By Company
Pharming Group NV
Takeda
CSL Limited
iBio Inc.
BioCryst Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Segment by Type
C1 Esterase Inhibitor
Kallikrein Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Segment by Distribution Channel
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Hereditary Angioedema market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Hereditary Angioedema, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Hereditary Angioedema industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Hereditary Angioedema in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Distribution Channel, Volume and Revenue analysis of Each Distribution Channel in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Hereditary Angioedema introduction, etc. Hereditary Angioedema Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Hereditary Angioedema market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.